JP2012050465A5 - - Google Patents

Download PDF

Info

Publication number
JP2012050465A5
JP2012050465A5 JP2011270236A JP2011270236A JP2012050465A5 JP 2012050465 A5 JP2012050465 A5 JP 2012050465A5 JP 2011270236 A JP2011270236 A JP 2011270236A JP 2011270236 A JP2011270236 A JP 2011270236A JP 2012050465 A5 JP2012050465 A5 JP 2012050465A5
Authority
JP
Japan
Prior art keywords
human
inhibitor
mammal
dna segment
segment encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011270236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012050465A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012050465A publication Critical patent/JP2012050465A/ja
Publication of JP2012050465A5 publication Critical patent/JP2012050465A5/ja
Pending legal-status Critical Current

Links

JP2011270236A 2000-01-31 2011-12-09 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター Pending JP2012050465A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US17931000P 2000-01-31 2000-01-31
EP00200320.0 2000-01-31
EP00200320 2000-01-31
US60/179,310 2000-01-31
US18758000P 2000-03-07 2000-03-07
EP00200810 2000-03-07
EP00200810.0 2000-03-07
US60/187,580 2000-03-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001557910A Division JP2003521914A (ja) 2000-01-31 2001-01-31 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014075150A Division JP2014121337A (ja) 2000-01-31 2014-04-01 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター

Publications (2)

Publication Number Publication Date
JP2012050465A JP2012050465A (ja) 2012-03-15
JP2012050465A5 true JP2012050465A5 (https=) 2013-07-04

Family

ID=27439989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011270236A Pending JP2012050465A (ja) 2000-01-31 2011-12-09 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター
JP2014075150A Pending JP2014121337A (ja) 2000-01-31 2014-04-01 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014075150A Pending JP2014121337A (ja) 2000-01-31 2014-04-01 トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター

Country Status (4)

Country Link
US (2) US7067713B2 (https=)
JP (2) JP2012050465A (https=)
BE (1) BE2010C040I2 (https=)
FR (1) FR10C0054I2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003301332B2 (en) * 2002-10-17 2008-06-12 Pharming Intellectual Property B.V. Protein modification
CN100431604C (zh) * 2003-05-16 2008-11-12 法明知识产权股份有限公司 用于瞬时性治疗的具有短半衰期的c1抑制剂
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
FR2901707B1 (fr) * 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
CA2927695C (en) 2013-10-21 2022-03-01 Dyax Corp. Diagnosis and treatment of autoimmune diseases
WO2015061183A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
CN105828603A (zh) * 2013-12-24 2016-08-03 Lfb美国股份有限公司 肝素的转基因生产
US10214731B2 (en) 2015-05-28 2019-02-26 Cornell University Adeno-associated virus mediated delivery of C1E1 as a therapy for angioedema
CN113999875A (zh) * 2015-05-28 2022-02-01 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP4354146B1 (en) 2015-10-19 2026-04-15 Takeda Pharmaceutical Company Limited Immunoassay for the detection of cleaved high molecular weight kininogen
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
CN110769848A (zh) * 2017-05-16 2020-02-07 瑞士奥克特珐玛公司 C1-酯酶抑制剂制剂
CA3092163A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Treatment and prevention of pre-eclampsia
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
EP4366761A1 (en) 2021-07-09 2024-05-15 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034B1 (fr) 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
WO1991006650A1 (en) 1989-10-27 1991-05-16 Cetus Corporation C1 inhibitor muteins and uses thereof
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
US6713662B1 (en) * 1994-07-27 2004-03-30 Pharming Intellectual Property B.V. Production of collagen in the milk of transgenic mammals
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
CA2398707C (en) * 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals

Similar Documents

Publication Publication Date Title
JP2012050465A5 (https=)
Igbokwe et al. Aluminium toxicosis: a review of toxic actions and effects
Liikanen et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients
Golan et al. The role of the zinc transporter SLC30A2/ZnT2 in transient neonatal zinc deficiency
Zhang et al. Metabolizable Bi2Se3 nanoplates: biodistribution, toxicity, and uses for cancer radiation therapy and imaging
IN2014MN01781A (https=)
ES2826123T3 (es) Método de purificación de anticuerpos
ES2659185T3 (es) Levadura recombinante
CA2398707A1 (en) C1 inhibitor produced in the milk of transgenic mammals
JP2013504589A5 (https=)
CA2893478C (en) Dialysis composition
CN103153333B (zh) 补体因子h的纯化方法
Dong et al. Intratracheal administration of umbilical cord-derived mesenchymal stem cells attenuates hyperoxia-induced multi-organ injury via heme oxygenase-1 and JAK/STAT pathways
WO2014005466A1 (zh) 改善缺铁性贫血的产品及其制备方法
US20150329607A1 (en) Mutant ngal proteins and uses thereof
AR074398A1 (es) Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa
Kheiri et al. Comparison of the effects of iron oxide, as a new form of iron supplement, and ferrous sulfate on the blood levels of iron and total iron-binding globulin in the rabbit
CN101798344A (zh) 一种适用于从人尿中大规模富集白蛋白的方法
CN102441172A (zh) 高纯度凝血酶原复合物制品冷冻干燥稳定剂
CN101744798A (zh) 一种含钙枸橼酸盐浓缩抗凝血液透析液
JP2013517259A5 (https=)
CN103330952A (zh) 131I标记抗VEGFR2嵌合Fab及其应用
Yeom et al. Hepatic veno-occlusive disease may develop in secondary iron overloaded mice after allogeneic hematopoietic stem cell transplantation with total body irradiation
CN204656552U (zh) 可用于脓毒症病人血液清洗的广谱磁珠结构体
Gluhcheva et al. Chronic exposure to cobalt compounds—an in vivo study